David Malcom Rodman is Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS). They have made 8 open-market trades across 1 company since 2016, most recently 2026-08-10.
CIK 0001672659
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MLYS | 51,384 | $1.0M |
| NVLS | 11,368 | $109K |
| Total | $1.2M |
Shares reported on the most recent Form 4, priced at the 2026-08-12 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLYS | SELL · 10b5-1 | 2026-08-10 | 2026-08-12 | $27.09 | $59K | -5.0% | +5.8% | — |
| MLYS | SELL · 10b5-1 | 2026-07-17 | 2026-07-20 | $26.53 | $11K | -1.4% | +1.5% | — |
| MLYS | SELL · 10b5-1 | 2026-07-13 | 2026-07-15 | $27.28 | $557K | +0.9% | -4.8% | -22.1% |
| MLYS | SELL · 10b5-1 | 2026-07-09 | 2026-07-10 | $30.30 | $66K | -1.7% | -0.5% | -18.6% |
| MLYS | SELL · 10b5-1 | 2026-06-15 | 2026-06-17 | $24.19 | $350K | +4.4% | +4.7% | +11.8% |
| MLYS | SELL · 10b5-1 | 2026-06-10 | 2026-06-12 | $24.20 | $206K | +10.1% | +15.4% | +22.4% |
| MLYS | SELL · 10b5-1 | 2026-05-18 | 2026-05-19 | $27.55 | $11K | +16.8% | -7.4% | -2.2% |
| MLYS | SELL · 10b5-1 | 2026-05-11 | 2026-05-13 | $28.91 | $653K | +11.3% | -12.4% | +1.5% |
| MLYS | SELL · 10b5-1 | 2026-04-17 | 2026-04-21 | $31.33 | $13K | +0.7% | +4.0% | -8.1% |
| MLYS | SELL · 10b5-1 | 2026-04-13 | 2026-04-15 | $26.89 | $549K | -11.1% | -9.7% | -10.2% |
| MLYS | SELL · 10b5-1 | 2026-04-09 | 2026-04-13 | $27.38 | $59K | +4.9% | -1.0% | +1.6% |
| MLYS | SELL · 10b5-1 | 2026-03-17 | 2026-03-17 | $25.65 | $11K | -3.5% | +24.6% | -2.6% |
| MLYS | SELL · 10b5-1 | 2026-03-12 | 2026-03-16 | $26.60 | $1.1M | -8.0% | +18.6% | -6.9% |
| MLYS | SELL | 2026-03-09 | 2026-03-10 | $26.84 | $58K | -15.0% | -4.0% | -20.6% |
| MLYS | SELL · 10b5-1 | 2026-02-17 | 2026-02-17 | $27.59 | $12K | +5.1% | -16.4% | -5.3% |
| MLYS | SELL | 2026-02-12 | 2026-02-13 | $27.93 | $570K | +5.2% | -6.7% | -1.1% |
| MLYS | SELL | 2026-02-09 | 2026-02-11 | $30.21 | $66K | +1.8% | -11.0% | -0.5% |
| MLYS | SELL | 2026-01-20 | 2026-01-20 | $32.10 | $13K | -1.7% | -10.7% | -4.3% |
| MLYS | SELL | 2026-01-13 | 2026-01-15 | $32.66 | $623K | +3.1% | -11.0% | -3.1% |
| MLYS | SELL | 2026-01-09 | 2026-01-13 | $32.56 | $277K | +2.6% | -13.5% | -15.7% |
| MLYS | SELL | 2026-01-02 | 2026-01-06 | $35.25 | $9.3M | -8.9% | -21.5% | -21.4% |
| MLYS | SELL · 10b5-1 | 2025-10-15 | 2025-10-15 | $43.01 | $892K | -6.2% | -5.5% | -23.8% |
| MLYS | SELL · 10b5-1 | 2025-09-15 | 2025-09-16 | $36.00 | $819K | +6.9% | +14.8% | -3.7% |
| MLYS | SELL · 10b5-1 | 2025-08-13 | 2025-08-14 | $12.93 | $294K | +6.6% | +155.5% | +234.0% |
| MLYS | SELL · 10b5-1 | 2025-07-14 | 2025-07-15 | $14.59 | $332K | -1.6% | -2.9% | +195.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.